Insulin degludec

Green-G

Brand Name(s):Tresiba

Indication:Diabetes Type 1& 2

Rationale:

Considered:Nov-12

Review Date:May-22

Comments:
Updated NG 17- diagnosis and management diagnosis and management & NICE NG28 Update Type 2 diabetes in adults: management
May 2017
…………………………
NICE guidelines [NG18]
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Full document available at:http://www.nice.org.uk/guidance/ng18
Aug 2015
…………………………
NICE NG17
Type 1 diabetes in adults: diagnosis and management
Full details available at:http://www.nice.org.uk/guidance/ng17/resources/type-1-diabetes-in-adults-diagnosis-and-management-1837276469701
Aug 2015
…………………………
Refer to the Doncaster and Bassetlaw Formulary for the place it’s therapy
http://medicinesmanagement.doncasterpct.nhs.uk/page.asp?cpath=103
Jan 2015

NICE
ESNM24 available at:http://publications.nice.org.uk/esnm24-type-1-diabetes-insulin-degludec-esnm24
Sept 2013

…………………………
Insulin degludec (Tresiba) is available in prefilled pen devices (known as FlexTouch) in two strengths: 100 units/mL; and 200 units/mL. The 100 units/mL strength is also available in cartridge form (called Penfill). The 200 units/mL strength is higher than that of other existing basal insulin products in the UK. Ensure the correct insulin product and strength is prescribed and dispensed.

The dose-counter window of the Tresiba FlexTouch pen device shows the number of units that will be injected, irrespective of strength. Therefore no dose conversion is needed when transferring a patient from one strength of Tresiba to a different strength.

Patients should be trained on the correct use of Tresiba products, and always visually verify the dialled units on the dose counter of the prefilled pen device (irrespective of strength). Advise patients to seek medical advice immediately if they think they have administered an incorrect dose of Tresiba

MHRA Drug Safety Information April 2013